Switch to ATV/r monotherapy

Slides:



Advertisements
Similar presentations
Switch to ATV + r-containing regimen - SWAN - SLOAT.
Advertisements

Comparison of INSTI vs PI  FLAMINGO  GS  ACTG A5257.
Switch to ATV/r monotherapy - ATARITMO - Swedish Study - ACTG A OREY.
Switch to ATV/r + RAL  HARNESS Study. ATV/r 300/100 mg qd + TDF/FTC N = 37 N = 72 ATV/r 300/100 mg qd + RAL 400 mg bid  Design Randomisation 2: 1 Open-label.
Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.
Switch to ATV/r + 3TC  SALT Study. ATV/r 300/100 mg qd + 2 NRTI (investigator-selected) N = 143 ATV/r 300/100 mg + 3TC 300 mg qd  Design Randomisation*
Switch to ATV/r-containing regimen  ATAZIP. Mallolas J, JAIDS 2009;51:29-36 ATAZIP ATAZIP Study: Switch LPV/r to ATV/r  Design  Endpoints –Primary:
Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
Switch to ATV/r monotherapy  ATARITMO  Swedish Study  ACTG A5201  OREY  MODAt Study.
Switch to ATV-containing regimen  ARIES Study  INDUMA Study  ASSURE Study.
Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.
Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.
Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
Comparison of PI vs PI  ATV vs ATV/r BMS 089  LPV/r mono vs LPV/r + ZDV/3TCMONARK  LPV/r QD vs BIDM M A5073  LPV/r + 3TC vs LPV/r + 2 NRTIGARDEL.
Switch to ATV ± r-containing regimen  SWAN Study  SLOAT Study.
Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
Clinical development programme for Second-Line treatment Anton Pozniak World AIDS Conference, July 2014.
Switch to ATV- or ATV/r-containing regimen Switch to ATV/r-containing regimen  ATAZIP Switch to ATV ± r-containing regimen  SWAN Study  SLOAT Study.
Switch to RAL-containing regimen  Canadian Study  CHEER  Montreal Study  EASIER  SWITCHMRK  SPIRAL  Switch ER.
Switch to ATV/r monotherapy  ATARITMO  Swedish Study  ACTG A5201  OREY  MODAt Study.
Switch to PI/r monotherapy
Comparison of PI vs PI ATV vs ATV/r BMS 089
ARV-trial.com Switch to TDF/FTC/EFV AI Study 1.
Comparison of INSTI vs INSTI
Comparison of INSTI vs PI
Switch to PI/r + 3TC vs PI/r monotherapy
ARV-trial.com Switch to ATV/r + 3TC ATLAS-M Study.
ARV-trial.com Switch to D/C/F/TAF EMERALD Study 1.
Switch to DTG + RPV Switch to DTG + RPV SWORD Study
Switch to DTG + 3TC ASPIRE Study.
NRTI-sparing SPARTAN PROGRESS RADAR NEAT001/ANRS 143 A VEMAN
Switch to DTG-containing regimen
Comparison of NRTI combinations
Comparison of PI vs PI ATV vs ATV/r BMS 089
Switch to E/C/F/TAF + DRV
Switch to LPV/r monotherapy
Switch to LPV/r monotherapy
Switch to BIC/FTC/TAF GS-US GS-US GS-US
Switch to DRV/r monotherapy
Switch to LPV/r monotherapy
Comparison of NNRTI vs PI/r
Comparison of PI vs PI ATV vs ATV/r BMS 089
Comparison of PI vs PI ATV vs ATV/r BMS 089
Comparison of PI vs PI ATV vs ATV/r BMS 089
Switch to LPV/r monotherapy
Switch to ATV- or ATV/r-containing regimen
Switch to RAL-containing regimen
ARV-trial.com Switch to DRV/r + RPV PROBE Study 1.
Comparison of INSTI vs INSTI
Comparison of NNRTI vs PI/r
Switch to RAL-containing regimen
Switch to LPV/r monotherapy
Comparison of PI vs PI ATV vs ATV/r BMS 089
ARV-trial.com Switch to TDF/FTC/EFV AI Study 1.
Switch to DTG-containing regimen
Switch to ATV/r monotherapy
Switch to LPV/r monotherapy
NRTI-sparing SPARTAN PROGRESS RADAR NEAT001/ANRS 143 A VEMAN
Switch to LPV/r monotherapy
ARV-trial.com Switch to ATV/r + RAL HARNESS Study 1.
ARV-trial.com Switch to DTG/ABC/3TC STRIIVING NEAT
Comparison of NRTI combinations
Comparison of NRTI combinations
Comparison of PI vs PI ATV vs ATV/r BMS 089
Switch to LPV/r monotherapy
ARV-trial.com Switch to FTC + ddI + EFV ALIZE 1.
Comparison of NNRTI vs NNRTI
Comparison of PI vs PI ATV vs ATV/r BMS 089
Presentation transcript:

Switch to ATV/r monotherapy ARV-trial.com Switch to ATV/r monotherapy ATARITMO Swedish Study ACTG A5201 OREY MODAt Study 1

OREY Study: Switch to ATV/r monotherapy ARV-trial.com OREY Study: Switch to ATV/r monotherapy Design Open-label Single-arm Pilot trial W48 HIV+ No history of prior virologic failure On ATV/r + 2 NRTIs ≥ 8 weeks HIV-1 RNA < 50 c/mL ≥ 24 weeks N = 61 Switch to ATV/r 300/100 mg qd monotherapy Primary endpoint Proportion of patients with virologic rebound (HIV-1 RNA ≥ 400 c/mL) or treatment discontinuation by W48 OREY Pulido F, EACS 2009;Abs. PS4/6

OREY Study: Switch to ATV/r monotherapy Mean duration of prior ATV/r therapy: 84 weeks Use of PI prior to ATV/r: 59% Median CD4 cell count/mm3 at inclusion: 514 Outcome at Week 48 Treatment failure, N = 13: 21% (95% CI: 11.9 -33.7%) Virologic rebound ≥ 400 c/mL, N = 7: 12% Virologic rebound ≥ 50 c/ml, N = 16: 27% Maintenance of HIV-1 RNA suppression < 50 c/mL: 67% Genotype at virologic rebound > 400 c/ml, N = 7 ; Major PI resistance in 1/7 + 1 post W48 Grade 3 or 4 total bilirubin: 64% AE leading to discontinuation, N = 1 Conclusion Pilot study of ATV/r monotherapy showing maintenance of virologic suppression in 79% of patients OREY Pulido F, EACS 2009;Abs. PS4/6